Passa al contenuto
Merck
Tutte le immagini(1)

Key Documents

SAB4200047

Sigma-Aldrich

Anti-BRD7 antibody, Rat monoclonal

clone BRM 2D3, purified from hybridoma cell culture

Sinonimo/i:

Anti-BP75, Anti-Bromodomain containing 7, Anti-CELTIX1, Anti-NAG4, Monoclonal Anti-BRD7 antibody produced in rat

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali


About This Item

Codice UNSPSC:
12352203
NACRES:
NA.41

Origine biologica

rat

Coniugato

unconjugated

Forma dell’anticorpo

purified from hybridoma cell culture

Tipo di anticorpo

primary antibodies

Clone

BRM 2D3, monoclonal

Forma fisica

buffered aqueous solution

PM

antigen ~80 kDa

Reattività contro le specie

rat, mouse, monkey, human, bovine, canine

Confezionamento

antibody small pack of 25 μL

tecniche

immunocytochemistry: suitable
immunoprecipitation (IP): suitable
western blot: 0.5-1.0 μg/mL using HeLa cells extract

Isotipo

IgG2a

N° accesso UniProt

Condizioni di spedizione

dry ice

Temperatura di conservazione

−20°C

modifica post-traduzionali bersaglio

unmodified

Informazioni sul gene

human ... BRD7(29117)

Categorie correlate

Descrizione generale

Monoclonal Anti-BRD7 (rat IgG2a isotype) is derived from the hybridoma BRM 2D3 produced by the fusion of mouse myeloma cells (P3X63Ag8.653) and splenocytes from rat immunized with a fusion protein expressing a fragment of human BRD7. Bromodomain containing (BRD7) is a novel bromodomain gene.

Applicazioni

Monoclonal Anti-BRD7 antibody produced in rat has been used in several immunochemical techniques including
  • immunoblotting
  • immunoprecipitation
  • immunocytochemistry

Azioni biochim/fisiol

Bromodomain containing (BRD7) inhibits cell growth and cell cycle progression by transcriptional regulation of some cell cycle-related genes as well as some important molecules involved in ras/mitogen-activated protein kinase(MEK)/extracellular-signal-regulated kinase (ERK) and retinoblastoma tumor suppressor protein (RB)/ E2 factor (E2F) pathways. Its transcriptional down regulation has been shown to be critical to the pathogenesis of nasopharyngeal carcinoma (NPC). Specifically, DNA methylation decreases the expression of BRD7 in NPC cells. Furthermore, DNA methylation of BRD7 promoter is increased in the tumor and in matched blood samples from NPC patients than in blood samples from healthy individuals. Therefore, it has been suggested that DNA methylation of BRD7 promoter might act as a potential diagnostic marker in NPC.

Stato fisico

Solution in 0.01M phosphate buffered saline pH 7.4, containing 15 mM sodium azide.

Esclusione di responsabilità

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Non trovi il prodotto giusto?  

Prova il nostro Motore di ricerca dei prodotti.

Codice della classe di stoccaggio

10 - Combustible liquids

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable


Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Promoter methylation inhibits BRD7 expression in human nasopharyngeal carcinoma cells
Liu H, et al.
BMC Cancer, 8(1), 253-253 (2008)
The transcriptional regulation role of BRD7 by binding to acetylated histone through bromodomain
Cong P, et al.
Journal of Cellular Biochemistry, 97(4), 882-892 (2006)
Nasopharyngeal carcinoma-review of the molecular mechanisms of tumorigenesis
Chou J, et al.
Head & Neck, 30(7), 946-963 (2008)
Junichi Yamamoto et al.
Nature chemical biology, 16(11), 1208-1217 (2020-09-23)
The immunomodulatory drug (IMiD) thalidomide and its derivatives lenalidomide and pomalidomide are therapeutic agents used in the treatment of multiple myeloma. Although pomalidomide offers considerable clinical benefits to patients with lenalidomide-resistant multiple myeloma, the molecular mechanisms underlying its superior efficacy

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.